Essential thrombocythemia

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

5 regimens on this page
7 variants on this page


Untreated

Aspirin & Anagrelide

back to top

Regimen #1

Study Evidence Comparator Efficacy
Harrison et al. 2005 (MRC PT-1) Phase III Aspirin & Hydroxyurea Seems to have inferior composite primary end point

Therapy

  • Anagrelide (Agrylin) 0.5 mg PO twice per day ("Doses were subsequently adjusted to maintain the platelet count at less than 400 x 109/L.")
  • Aspirin 75 mg (100 mg in Australia) PO once per day

Regimen #2

Study Evidence Comparator Efficacy
Gisslinger et al. 2013 (ANAHYDRET) Phase III Hydroxyurea +/- Aspirin Noninferior

Therapy

  • Anagrelide (Agrylin) 0.5 mg PO twice per day ("increased until maintenance of the platelet count at normal (less than or equal to 450 x 109/L) or close to normal levels (450 to 600 x 109/L)")
  • Neither aspirin nor Clopidogrel (Plavix) were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion

References

  1. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. link to original article contains verified protocol PubMed content property of HemOnc.org
  2. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. Epub 2013 Jan 11. link to original article contains verified protocol link to PMC article PubMed

Aspirin & Hydroxyurea

back to top

Regimen #1

Study Evidence Comparator Efficacy
Harrison et al. 2005 (MRC PT-1) Phase III Aspirin & Anagrelide Seems to have superior composite primary end point

Chemotherapy

  • Hydroxyurea (Hydrea) 500 to 1000 mg PO once per day ("Doses were subsequently adjusted to maintain the platelet count at less than 400 x 109/L.")
  • Aspirin 75 mg (100 mg in Australia) PO once per day

Regimen #2

Study Evidence Comparator Efficacy
Gisslinger et al. 2013 (ANAHYDRET) Phase III Anagrelide +/- Aspirin Noninferior

Chemotherapy

  • Hydroxyurea (Hydrea) 1500 mg PO once per day ("increased until maintenance of the platelet count at normal (less than or equal to 450 x 109/L) or close to normal levels (450 to 600 x 109/L)")
  • Neither aspirin nor Clopidogrel (Plavix) were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion

References

  1. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. link to original article contains verified protocol PubMed
  2. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. Epub 2013 Jan 11. link to original article contains verified protocol link to PMC article PubMed

Hydroxyurea (Hydrea)

back to top

Regimen

Study Evidence Comparator Efficacy
Cortelazzo et al. 1995 Phase III Observation Superior thrombotic episode rate

Chemotherapy

  • Hydroxyurea (Hydrea) 15 mg/kg/day PO
    • Doses were subsequently adjusted to maintain the platelet count at less than 600 x 109/L without lowering the WBC count below 4 x 109/L

References

  1. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995 Apr 27;332(17):1132-6. link to original article contains verified protocol PubMed

Observation

back to top

Regimen

Study Evidence Comparator Efficacy
Cortelazzo et al. 1995 Phase III Hydroxyurea Inferior thrombotic episode rate

No active antineoplastic treatment; used as a comparator arm.

References

  1. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995 Apr 27;332(17):1132-6. link to original article contains verified protocol PubMed

Peginterferon alfa-2a (Pegasys)

back to top

Regimen

Study Evidence
Quintás-Cardama et al. 2009 Phase II

This trial had several dose de-escalations due to toxicity and the dose here is the reported final starting dose.

Immunotherapy

Continued for as long as the patient experiences clinical benefit

References

  1. Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009 Nov 10;27(32):5418-24. Epub 2009 Oct 13. link to original article contains protocol link to PMC article PubMed
    1. Update: Quintás-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek S. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood. 2013 Aug 8;122(6):893-901. Epub 2013 Jun 19. link to original article link to PMC article PubMed
    2. Update: Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, Estrov Z, Kantarjian H, Verstovsek S. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017 Mar 10. [Epub ahead of print] link to original article link to PMC article PubMed

Relapsed/Refractory

Peginterferon alfa-2a (Pegasys)

back to top

Regimen

Study Evidence
Verger et al. 2015 Observational

Verger et al. 2015 do not specify a protocol but rather point to the European LeukemiaNet guidelines from 2011. All patients in this study had CALR mutations.

Immunotherapy

References

  1. Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter MH, Ianotto JC, Yassin MA, Al-Dewik N, Carillo S, Legouffe E, Ugo V, Chomienne C, Kiladjian JJ. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015 Dec 10;126(24):2585-91. Epub 2015 Oct 20. link to original article does not contain protocol PubMed